"FDA Greenlights Zurzuvae: First-Ever Pill for Postpartum Depression"
The FDA has approved the first oral medication, zuranolone (brand name Zurzuvae), to treat postpartum depression. Postpartum depression affects about 1 in 7 women following childbirth and can have serious consequences for both the mother and child. Previously, the only FDA-approved treatment was an IV injection, but the new pill can be taken at home. Zurzuvae acts quickly, providing relief during the crucial bonding period after childbirth. However, researchers caution that postpartum depression has multiple underlying causes and that social support, longer maternity leave, flexible work schedules, and universal child care are also needed. The medication's side effects include drowsiness and dizziness.
- FDA approves first postpartum depression drug, Zurzuvae The Washington Post
- FDA Approves First Pill for Postpartum Depression The New York Times
- FDA decision on first-ever postpartum depression pill expected by tomorrow 9NEWS
- FDA approves first postpartum depression pill in the US CNN
- FDA could soon approve first-ever postpartum treatment pill KCRA 3
Reading Insights
0
1
2 min
vs 3 min read
81%
547 → 102 words
Want the full story? Read the original article
Read on The Washington Post